IMMUNEERING CORP - CLASS A (IMRX:NASDAQ)

$4.55 0.27 (6.3084%)

watchlist-icon
search-icon
Profile Icon

Most Recent Average Sentiment Analysis Score (0 to 100): 69

negative-sentiment
Negative [0, 35)
neutral-sentiment
Neutral [35, 65]
positive-sentiment
Positive (65, 100]
Visualize Sentiment Trendline

Analysed IMMUNEERING CORP - CLASS A (IMRX:NASDAQ) News Sources

Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival

17-03-2026

yahoo.com

Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference

06-04-2026

yahoo.com

Immuneering CEO Touts 64% 12-Month Survival in Pancreatic Cancer; Phase 3 Launch Nears

14-04-2026

marketbeat.com

Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond

20-04-2026

yahoo.com

Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting

21-04-2026

yahoo.com

We're Hopeful That Immuneering (NASDAQ:IMRX) Will Use Its Cash Wisely

06-05-2026

yahoo.com

Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates

15-05-2026

yahoo.com

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy

21-05-2026

yahoo.com

Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO

01-06-2026

yahoo.com

IMRX Stock On Track For Worst Day In Nearly 5 Months — What’s Driving The Selloff?

01-06-2026

stocktwits.com

IMMUNEERING CORP - CLASS A (IMRX:NASDAQ) Sentiment Trend

0 25 50 75 100 76 84 91 64 75 89 73 82 53 2 17-03-2026 06-04-2026 14-04-2026 20-04-2026 21-04-2026 06-05-2026 15-05-2026 21-05-2026 01-06-2026 #1 #2 #3 #4 #5 #6 #7 #8 #9 #10 Negative < 35 Neutral 35–65 Positive > 65 View FAQ

IMMUNEERING CORP - CLASS A (IMRX:NASDAQ) FAQs

toggle

What is the current price of IMMUNEERING CORP - CLASS A (IMRX:NASDAQ)?

The current price of IMMUNEERING CORP - CLASS A (IMRX:NASDAQ) is $4.55.


toggle

IMMUNEERING CORP - CLASS A (IMRX:NASDAQ) absolute price change since previous trading day?

The absolute price change of IMMUNEERING CORP - CLASS A (IMRX:NASDAQ) since the previous trading day is $0.27.


toggle

IMMUNEERING CORP - CLASS A (IMRX:NASDAQ) percentage price change since previous trading day?

The percentage price change of IMMUNEERING CORP - CLASS A (IMRX:NASDAQ) since the previous trading day is 6.3084%.


toggle

What is the most recent average sentiment score for IMMUNEERING CORP - CLASS A (IMRX:NASDAQ)?

The most recent average sentiment score for IMMUNEERING CORP - CLASS A (IMRX:NASDAQ) is 69 out of 100.


toggle

What is the most recent average sentiment for IMMUNEERING CORP - CLASS A (IMRX:NASDAQ)?

The most recent sentiment for IMMUNEERING CORP - CLASS A (IMRX:NASDAQ) is .


SEC-8K** Filing Available For IMMUNEERING CORP - CLASS A (IMRX:NASDAQ)

** material developments that could impact a company's financial condition or stock price.

Author: MattELab

X Icon

GitHub Icon

MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.